HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma

作者：Josep Tabernero, Lin Shen, Elena Elimova, Geoffrey Y. Ku, Tianshu Liu, Kohei Shitara, Xiao Lin, Lisa Boyken, Huiyan Li, Jonathan Grim, Jaffer A. Ajani · 发表于：Future Oncology · 年份：2022 · DOI：10.2217/fon-2022-0595 · 被引用次数：64 · 研究领域：Gastric Cancer Management and Outcomes、HER2/EGFR in Cancer Research、Peptidase Inhibition and Analysis

HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited. Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. Preliminary data suggest that dual targeting of the HER2 and PD-1 pathways could further improve upon the results achieved with targeting either pathway alone. Here, we describe the design of HERIZON-GEA-01, a global, randomized, open-label, active-comparator, Phase III study to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy with or without tislelizumab to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for patients with advanced/metastatic HER2-positive GEAs.